Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer
Authors:
Open Access
- 13 November 2023
- journal article
- research article
- Published by Springer Nature in Biological Procedures Online
- Vol. 25 (1) , 1-17
Abstract
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide, primarily due to its propensity for metastasis. Patients diagnosed with localized primary cancer have higher survival rates than those with metastasis. Thus, it is imperative to discover biomarkers for the early detection of NSCLC and the timely prediction of tumor metastasis to improve patient outcomes. Methods: Here, we utilized an integrated approach to isolate and characterize plasma exosomes from NSCLC patients as well as healthy individuals. We then conducted proteomics analysis and parallel reaction monitoring to identify and validate the top-ranked proteins of plasma exosomes. Results: Our study revealed that the proteome in exosomes from NSCLC patients with metastasis was distinctly different from that from healthy individuals. The former had larger diameters and lower concentrations of exosomes than the latter. Furthermore, among the 1220 identified exosomal proteins, we identified two distinct panels of biomarkers. The first panel of biomarkers (FGB, FGG, and VWF) showed potential for early NSCLC diagnosis and demonstrated a direct correlation with the survival duration of NSCLC patients. The second panel of biomarkers (CFHR5, C9, and MBL2) emerged as potential biomarkers for assessing NSCLC metastasis, of which CFHR5 alone was significantly associated with the overall survival of NSCLC patients. Conclusions: These findings underscore the potential of plasma exosomal biomarkers for early NSCLC diagnosis and metastasis prediction. Notably, CFHR5 stands out as a promising prognostic indicator for NSCLC patients. The clinical utility of exosomal biomarkers offers the potential to enhance the management of NSCLC.Keywords
Funding Information
- the Corbett Estate Fund for Cancer Research (62285-531021-41800, 62285-531021-51800, 62285-531021-61800, and 62285-531021-71800)
- National Natural Science Foundation of China (82104943, 82174245, 82174017, and 21675110)
This publication has 71 references indexed in Scilit:
- “Sentinel” Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary DiseasePLOS ONE, 2014
- Different exosome cargo from plasma/bronchoalveolar lavage in non‐small‐cell lung cancerGenes, Chromosomes and Cancer, 2014
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung CancerPLOS ONE, 2013
- Complement factor H related proteins (CFHRs)Molecular Immunology, 2013
- Prospects for population screening and diagnosis of lung cancerThe Lancet, 2013
- Extracellular vesicles: Exosomes, microvesicles, and friendsJournal of Cell Biology, 2013
- C3 glomerulonephritis and CFHR5 nephropathyNephrology Dialysis Transplantation, 2012
- A complement to kidney disease: CFHR5 nephropathyThe Lancet, 2010
- Upregulation of plasma C9 protein in gastric cancer patientsProteomics, 2010
- A Practical Platform for Blood Biomarker Study by Using Global Gene Expression Profiling of Peripheral Whole BloodPLOS ONE, 2009